Research Analysts’ Recent Ratings Updates for Sabra Healthcare REIT (SBRA)

Sabra Healthcare REIT (NASDAQ: SBRA) has recently received a number of price target changes and ratings updates:

• 7/22/2026 – Sabra Healthcare REIT was given a new $25.00 price target by UBS Group AG.
• 7/22/2026 – Sabra Healthcare REIT had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 7/22/2026 – Sabra Healthcare REIT had its price target raised by Robert W. Baird from $22.00 to $23.00. They now have a “neutral” rating on the stock.
• 7/22/2026 – Sabra Healthcare REIT had its “market outperform” rating reaffirmed by Citigroup Inc..
• 7/22/2026 – Sabra Healthcare REIT had its price target raised by Truist Financial Corporation from $22.00 to $24.00. They now have a “buy” rating on the stock.
• 7/22/2026 – Sabra Healthcare REIT had its price target raised by Citizens Jmp from $23.00 to $25.00. They now have a “market outperform” rating on the stock.
• 7/8/2026 – Sabra Healthcare REIT had its price target lowered by UBS Group AG from $22.00 to $21.00. They now have a “neutral” rating on the stock.
• 7/8/2026 – Sabra Healthcare REIT was downgraded by Truist Financial Corporation from “buy” to “hold”.
• 7/8/2026 – Sabra Healthcare REIT was upgraded by Truist Financial Corporation from “hold” to “buy”. They now have a $22.00 price target on the stock.
• 7/7/2026 – Sabra Healthcare REIT is now covered by Barclays PLC. They set an “overweight” rating and a $21.00 price target on the stock.
• 6/28/2026 – Sabra Healthcare REIT was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/22/2026 – Sabra Healthcare REIT was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $19.00 price target on the stock, down from $24.00.
• 6/20/2026 – Sabra Healthcare REIT was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/18/2026 – Sabra Healthcare REIT was given a new $19.00 price target by UBS Group AG.
• 6/18/2026 – Sabra Healthcare REIT had its price target lowered by Scotiabank from $22.00 to $19.00. They now have a “sector perform” rating on the stock.
• 6/17/2026 – Sabra Healthcare REIT is now covered by Raymond James Financial, Inc.. They set an “underperform” rating on the stock.
• 6/4/2026 – Sabra Healthcare REIT was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 6/1/2026 – Sabra Healthcare REIT had its price target raised by Wells Fargo & Company from $22.00 to $23.00. They now have an “overweight” rating on the stock.

Sabra Healthcare REIT Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 5.4%. The ex-dividend date was Friday, May 15th. Sabra Healthcare REIT’s dividend payout ratio is currently 190.48%.

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.